Clinical Research Of The Protective Effect And Mechanism Of Erigeron Injection On Patients With Myocardial Ischemia-reperfusion Injury

Objective:The aim of the study is to observe the protective effect of "Erigeron Injection" on patients with myocardial ischemia-reperfusion injury, and is also to explore its possible mechanism and provide a scientific basis for myocardial ischemia-reperfusion injury by using Chinese medicine.Methods:Cardiovascular in-patient Department for "acute chest pain" as the research object, would be consistent with the inclusion criteria. Select 60 patients.The 60 cases are randomly divided into control group (20 cases),Creatine phosphoric acid sodium treatment group(20 cases) and Erigeron treatment group (20 cases).All groups get based treatment including ACEI or ARB, nitrates, low molecular weight heparin, enteric-coated aspirin Lin, clopidogrel, (3-receptor blockers, and necessary blood pressure therapy. Creatine phosphoric acid sodium treatment group needs creatine phosphoric acid sodiumeach 1g, once daily; the Erigeron treatment group also requires intravenous injection fleabane, each 60ml, once a day.The course is about 2 to 7 days. Using any other Chinese medicine during the treatment is prohibitted. Indicators including of serum IL-6, TNF, SOD, MDA and NO levels are observed before and after treatment.Results:1. Compared with the control group, using Erigeron Injection can reduce the level of TNF-a and IL-6 on patients with myocardial ischemia-reperfusion injury (P<0.05).2. Compared with the control group, using Erigeron Injection can reduce the level of MDA and increase the level of SOD on patients with myocardial ischemia-reperfusion injury (P<0.05).3. Compared with the control group, using Erigeron Injection can increase the level of NO on patients with myocardial ischemia-reperfusion injury (P<0.05)4. Compared with Creatine phosphoric acid sodium treatment group, Erigeron treatment group has no significant difference in the lelve of serum IL-6, TNF, SOD, MDA and NO (P>0.05).Conclusion:1. Erigeron Injection has positive curative effect on ACS patients with myocardial ischemia-reperfusion injury after PCI, and its mechanism may be related with inhibitling the inflammatory response, scavenging oxygen free radicals and others.2. There is no significant difference between Creatine phosphoric acid sodium and Erigeron for patients with myocardial ischemia-reperfusion injury.